Related Experiment Video

Updated: May 15, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pharmacotherapy for pneumococcal infections: an update

Susanna Esposito1, Nicola Principi

  • 1Pediatric Clinic 1, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milano, Italy. susanna.esposito@unimi.it

Expert Opinion on Pharmacotherapy
|December 22, 2012
PubMed

Insights

Pneumococcal disease management is challenging due to antibiotic resistance, especially in children. New vaccines may help, but protein-based vaccines are needed for complete protection against Streptococcus pneumoniae.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Pneumococcal diseases pose significant medical and economic burdens.
  • Children are the most vulnerable population to pneumococcal infections.

Purpose of the Study:

  • To review the optimal therapeutic strategies for pneumococcal resistance.
  • To analyze Streptococcus pneumoniae susceptibility and antibiotic pharmacokinetics/pharmacodynamics.

Main Methods:

  • Literature review of current therapeutic approaches.
  • Analysis of antibiotic efficacy against resistant Streptococcus pneumoniae strains.
  • Evaluation of pharmacokinetic and pharmacodynamic properties of antibiotics.

Main Results:

  • Antibiotic treatment for many pneumococcal diseases is hindered by resistant strains.
  • Drug limitations for pediatric use exacerbate treatment difficulties in children.
  • Emerging conjugate pneumococcal vaccines (PCV10, PCV13) show promise in reducing infection incidence and pathogen circulation.

Conclusions:

  • Effective treatment of pneumococcal infections is challenged by antibiotic resistance.
  • Pediatric populations face greater risks due to limited drug options.
  • Future development of broad-spectrum protein-based vaccines is crucial for comprehensive prevention of all pneumococcal infections.
Abstract

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP009208:53

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092

Published on: October 2, 2017

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...